BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26463704)

  • 1. Quantification of epidermal growth factor receptor (EGFR) in canine mammary tumours by ELISA assay: clinical and prognostic implications.
    Queiroga FL; Perez-Alenza MD; González-Gil A; Silván G; Peña L; Illera JC
    Vet Comp Oncol; 2017 Jun; 15(2):383-390. PubMed ID: 26463704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic implications of serum and tissue prolactin levels in canine mammary tumours.
    Queiroga FL; Pérez-Alenza MD; González Gil A; Silvan G; Peña L; Illera JC
    Vet Rec; 2014 Oct; 175(16):403. PubMed ID: 25096592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and Tissue Steroid Hormone Levels in Canine Mammary Tumours: Clinical and Prognostic Implications.
    Queiroga FL; Pérez-Alenza D; González-Gil A; Silván G; Peña L; Illera JC
    Reprod Domest Anim; 2015 Oct; 50(5):858-65. PubMed ID: 26332137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and microvessel density in canine malignant mammary tumours.
    Carvalho MI; Guimarães MJ; Pires I; Prada J; Silva-Carvalho R; Lopes C; Queiroga FL
    Res Vet Sci; 2013 Dec; 95(3):1094-9. PubMed ID: 24091029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic value of c-met in canine mammary tumours.
    Chen YC; Chen YY; Liao JW; Chang SC
    Vet Comp Oncol; 2018 Dec; 16(4):670-676. PubMed ID: 30129270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues.
    Gama A; Gärtner F; Alves A; Schmitt F
    Res Vet Sci; 2009 Dec; 87(3):432-7. PubMed ID: 19464036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer.
    Campos LC; Silva JO; Santos FS; Araújo MR; Lavalle GE; Ferreira E; Cassali GD
    J Vet Diagn Invest; 2015 Jul; 27(4):531-5. PubMed ID: 26179096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer.
    Queiroga FL; Pérez-Alenza D; Silvan G; Peña L; Lopes CS; Illera JC
    Res Vet Sci; 2010 Dec; 89(3):396-403. PubMed ID: 20381105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer.
    de Andrés PJ; Illera JC; Cáceres S; Díez L; Pérez-Alenza MD; Peña L
    Vet Immunol Immunopathol; 2013 Apr; 152(3-4):245-51. PubMed ID: 23351639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive correlation of steroid hormones and EGF in canine mammary cancer.
    Queiroga FL; Pérez-Alenza D; Silvan G; Peña L; Illera JC
    J Steroid Biochem Mol Biol; 2009 May; 115(1-2):9-13. PubMed ID: 19429455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumour-associated macrophages in canine mammary tumours.
    Raposo T; Gregório H; Pires I; Prada J; Queiroga FL
    Vet Comp Oncol; 2014 Mar; 12(1):10-9. PubMed ID: 22533625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
    Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
    Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours.
    Guimarães MJ; Carvalho MI; Pires I; Prada J; Gil AG; Lopes C; Queiroga FL
    J Comp Pathol; 2014 Jan; 150(1):27-34. PubMed ID: 24060154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
    Kim NH; Lim HY; Im KS; Kim JH; Sur JH
    J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
    Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
    Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands: Prognostic Impact by a Multivariate Survival Analysis.
    Carvalho MI; Pires I; Prada J; Lobo L; Queiroga FL
    Vet Pathol; 2016 Nov; 53(6):1138-1146. PubMed ID: 27162119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases.
    Rasotto R; Berlato D; Goldschmidt MH; Zappulli V
    Vet Pathol; 2017 Jul; 54(4):571-578. PubMed ID: 28355108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
    Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
    Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
    Queiroga FL; Pires I; Lobo L; Lopes CS
    Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.